MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of ...

MBX Biosciences Names Steve Hoerter Chief Executive

MBX Biosciences appointed Steve Hoerter chairman and chief executive, effective immediately, succeeding Kent Hawryluk. Hoerter has served as executive chairman since November 2025 and joined the board ...

MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO

MBX Biosciences (MBX) announced on Monday that its Board of Directors has appointed Steve Hoerter, current executive chairman of the board, as its new chairman and chief executive officer, effective ...
Yahoo Finance

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

The live webcast for each presentation can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events ...
Yahoo Finance

MBX Biosciences Submits IND for Once-Monthly Obesity Drug

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Motley Fool

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run

MBX Biosciences develops precision peptide therapies targeting endocrine and metabolic disorders, with a pipeline including MBX 2109 (phase 2 for chronic hypoparathyroidism), MBX 1416 (phase 1 for ...

MBX Biosciences Announces CEO Transition and Leadership Updates

Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.
manilatimes

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
The Motley Fool

Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase

NYSEMKT: IEFA: $139.12 million (8.0% of AUM) NASDAQ: VONV: $101.89 million (5.9% of AUM) NASDAQ: VONG: $94.67 million (5.5% of AUM) NASDAQ: NVDA: $84.44 million (4.9% of AUM) NYSE: SGOV: $65.17 ...
Hosted on MSN

MBX Biosciences Obesity Day spotlights monthly GLP-1 hope and pipeline push

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key ...
Benzinga.com

MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study

MBX Biosciences, Inc. (NASDAQ:MBX) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase ...